The Stem Cell Podcast

Ep. 82: “Year in Review” Featuring Dr. Daylon James

Jan 3, 2017
Dr. Daylon James, assistant professor at Weill Cornell who studies stem cells for heart and reproductive disorders. He reviews the year’s big stories like Zika, iPSC progress, organoids, mitochondrial replacement, CRISPR therapies, and fertility preservation. Short, lively takes on advances, risks, and where stem cell research is heading.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

CRISPR Shows Somatic Therapeutic Potential

  • Somatic in vivo CRISPR editing can produce therapeutic benefit without altering the germline.
  • In mouse DMD models, AAV9-delivered CRISPR restored dystrophin expression and improved muscle function, showing clinical potential.
INSIGHT

First Human CRISPR Cell Therapy Trial Reported

  • CRISPR entered human trials in 2016 via edited immune cells for terminal lung cancer, marking a clinical milestone.
  • Cells were edited ex vivo to knock out a cancer-exploited gene, then reinfused to test safety and therapeutic effect.
ANECDOTE

Melton Retracted Betatrophin After Reproducibility Fails

  • Doug Melton retracted a high-profile betatrophin diabetes paper after independent failures to reproduce results.
  • Melton collaborated with other labs, published refutations, and acknowledged the mistake to move the field forward.
Get the Snipd Podcast app to discover more snips from this episode
Get the app